Pharmacovigilance in Azerbaijan

Pharmacovigilance in Azerbaijan: Current Status, Challenge and Future Prospects

Pharmacovigilance is an essential component of the healthcare system that aims to ensure the safety and efficacy of medications, particularly in post-market settings. In Azerbaijan, the importance of pharmacovigilance has been increasingly recognized as the country aligns itself with international standards and strives to modernize its healthcare system. Over the past few years, Azerbaijan has made significant progress in establishing a regulatory framework for pharmacovigilance, improving ADR reporting mechanisms, and collaborating with international organizations. This article explores the current state of pharmacovigilance in Azerbaijan, key regulatory developments, the ADR reporting system, and opportunities.

Regulatory Framework and Oversight

The pharmacovigilance landscape in Azerbaijan is shaped by a combination of national laws, regulatory bodies, and international commitments. The country has made substantial strides in developing a regulatory framework that aligns with international pharmacovigilance practices, particularly those endorsed by the World Health Organization (WHO) and the European Medicines Agency (EMA).

Key Regulatory Bodies

• Ministry of Health of the Republic of Azerbaijan (MoH): The Ministry is the central authority responsible for regulating public health and pharmaceutical activities, including pharmacovigilance. It oversees the registration of medicines, monitoring of their safety, and the implementation of post-market surveillance.
• The Analytical Expertise Center: This agency operates under the Ministry of Health and plays a key role in regulating pharmaceuticals, including the establishment of pharmacovigilance practices.

Azerbaijan’s pharmacovigilance system has been influenced by international best practices, particularly the European Union’s Good Pharmacovigilance Practices (GVP) guidelines. In addition, Azerbaijan is a member of the World Health Organization (WHO), which provides a global framework for pharmacovigilance activities. Azerbaijan’s commitment to aligning with the WHO’s International Pharmacovigilance Guidelines further strengthens the country’s regulatory approach.

---

Azerbaijan Pharmacovigilance Guidelines

PV Normative Documents:

1.Resolution N 503, 25.12.2019 on the approval of Regulation of the pharmacovigilance of medicinal products
2.Resolution № 39, 25.08.2020 on approval of the “Guidelines for Good Pharmacovigilance Practice”

Pharmacovigilance Requirements

MAH responsibility in Azerbaijan	Requirement
Pharmacovigilance System Master File (PSMF)	Yes
Qualified Person for Pharmacovigilance (QPPV)	Yes
Local QPPV/Local Contact Person for Pharmacovigilance (LCPPV)	Yes
Adverse Event reporting	Yes
Weekly local/global literature surveillance	Yes
Weekly local/global Regulatory intelligence monitoring	Yes
Routine PSUR/PBRER/DSUR submission	Yes
RMP submission	Yes
Local/global Signal detection	Yes
Risk Minimization Measures (RMM)	Yes
Additional Risk Minimization Measures (aRMM)	Yes

Adverse Drug Reaction (ADR) Reporting System

Effective pharmacovigilance is largely dependent on a robust ADR reporting system. In Azerbaijan, the national ADR reporting system is designed to collect and analyze reports of adverse events associated with medicinal products.

ADR Reporting Mechanisms

The Analytical Expertise Center manages the collection of ADR data. Healthcare professionals, including doctors and pharmacists, are encouraged to report any adverse drug reactions they encounter during clinical practice. Additionally, the system allows for reports from patients themselves, although patient participation in ADR reporting remains limited.

Azerbaijan’s electronic ADR reporting system (VigiFlow, a WHO-compliant database for collecting and analyzing ICSRs) was introduced in 2020 to streamline the process of submitting reports. This system allows healthcare professionals to enter data directly into an online platform, which facilitates faster processing and better tracking of adverse events (Azerbaijan Ministry of Health, 2024). Despite the introduction of electronic reporting, many healthcare providers still rely on paper-based systems, particularly in rural areas, which may lead to delays in ADR data collection.

Challenges in ADR Reporting

Underreporting of ADRs remains a significant challenge in Azerbaijan’s pharmacovigilance system. Data from recent studies show that only around 10-15% of ADRs are reported to the national system, which is considerably lower than global reporting levels (Abdullayev et al., 2024). To address this, Azerbaijan has undertaken initiatives such as:

• Training Programs: Workshops for healthcare professionals aim to improve the quality and quantity of ICSRs.
• Public Engagement: Campaigns to encourage ADR reporting by patients and caregivers.

International Collaboration and Global Integration

Azerbaijan’s pharmacovigilance efforts are increasingly aligned with international standards, particularly through its participation in the World Health Organization’s (WHO) Pharmacovigilance Program. As a member of the WHO, Azerbaijan contributes to the WHO Global Individual Case Safety Reports (ICSRs) database, which is a critical part of global pharmacovigilance efforts. Through this program, Azerbaijan collaborates with other countries to share safety information, detect global safety signals, and monitor adverse drug reactions more effectively.

In addition, Azerbaijan is working to integrate its pharmacovigilance practices with the European Medicines Agency (EMA) through the Eurasian Economic Union (EAEU), of which Azerbaijan is an observer country. The EAEU fosters greater regional cooperation and ensures that pharmacovigilance practices are harmonized across member states, improving the overall safety and monitoring of medicines in the region (European Union External Action, 2024).

These international collaborations have allowed Azerbaijan to adopt best practices in pharmacovigilance, enhance its regulatory capabilities, and improve the safety of medications in the country.

Pharmacovigilance in Azerbaijan: Opportunities and Future Directions

Azerbaijan has several opportunities to strengthen its pharmacovigilance system in the coming years:

1. Digitalization and AI: The integration of artificial intelligence (AI) and big data analytics could significantly enhance pharmacovigilance in Azerbaijan. AI-powered systems can help automate the detection of safety signals from ADR reports, enabling quicker identification of potential risks (Liu et al., 2024).
2. Public-Private Partnerships: Strengthening collaboration between government agencies, healthcare providers, pharmaceutical companies, and patient advocacy groups can help improve the effectiveness of pharmacovigilance activities. Pharmaceutical companies, in particular, can play a critical role in training healthcare professionals and raising public awareness about the importance of ADR reporting (Sultanov et al., 2024).
3. Training and Education: Expanding training programs for healthcare professionals, including doctors, pharmacists, and nurses, on the importance of pharmacovigilance and ADR reporting is crucial. Specialized education should also be integrated into medical and pharmacy curricula to ensure that future healthcare professionals are well-equipped to manage drug safety concerns.
4. Increased Public Awareness Campaigns: Launching nationwide campaigns to educate the public about ADRs and the importance of reporting them can help improve patient participation in pharmacovigilance efforts. Public awareness campaigns should focus on how to report ADRs and the role that patients play in enhancing drug safety.

Conclusion

Azerbaijan made significant progress in developing a pharmacovigilance system that meets international standards. Further development in this area by creating a more effective and comprehensive pharmacovigilance framework will ensure the safety of medicines, protect public health, and contribute to global efforts to monitor drug safety.

References

1. Abdullayev, M., Hasanov, Z., & Aliyev, V. (2024). Pharmacovigilance in Azerbaijan: A Review of Current Practices and Challenges. Journal of Drug Safety, 47(3), 187-195.
2. Azerbaijan Ministry of Health. (2024). Annual Report on Pharmacovigilance and Drug Safety. Ministry of Health of Azerbaijan.
3. European Union External Action. (2024). The Role of the Eurasian Economic Union in Regional Pharmacovigilance. EU External Relations.
4. Liu, Y., Chen, L., & Zhang, Z. (2024). The Role of AI in Advancing Pharmacovigilance Systems: A Global Perspective. Pharmaceutical Innovation, 13(2), 97-104.
5. Sultanov, A., Bektur, R., & Yeldesbayev, E. (2024). Strengthening Public-Private Partnerships for Effective Pharmacovigilance. Pharmaceutical Policy and Law, 29(3), 121-128.